Bayer Tianheng: Lenvatinib is approved for esophageal cancer indication.

Bayer TianHeng announced that the company has received the Drug Registration Certificate from the National Medical Products Administration. The self-developed global first-in-class EGFRHER3 bispecific ADC Lencanituzumab/Yizekang has been approved for second-line treatment of advanced esophageal cancer. This is the second indication approved for the drug in China, with the first being for the treatment of recurrent or metastatic nasopharyngeal cancer. The application for the treatment of locally advanced or metastatic triple-negative breast cancer has also been accepted. Sales of pharmaceuticals are subject to uncertainties influenced by factors such as policy and market conditions.